(Q33518761)

English

Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

0 references

1 reference

based on heuristic

inferred from title

author name string

J Craig Nelson

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

12-18

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Follow-up and family study of anxious depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

21 January 2018

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of concurrent anxiety on response to sertraline and imipramine in patients with chronic depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Anxious and nonanxious depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Major depressive subtypes and treatment response.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Temporal profiles of the course of depression during treatment. Predictors of pathways toward recovery in the elderly

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Major depressive disorder and panic disorder. Effects of comorbidity on treatment outcome with antidepressant medications.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Remission in depressed geriatric primary care patients: a report from the PROSPECT study

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Good treatment outcomes in late-life depression with comorbid anxiety

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

A rating scale for depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of second generation antidepressants in late-life depression: a meta-analysis of the evidence

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitative rating of depressive states

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Exactly what does the Hamilton Depression Rating Scale measure?

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

An Item Response analysis of the Hamilton Depression Rating Scale using shared data from two pharmaceutical companies

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report

1 reference

https://api.crossref.org/works/10.1002%2FDA.20632

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.20632

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

release_i3plc2rttzhbjpmo74ilunghm4

1 reference

https://api.fatcat.wiki/v0/release/i3plc2rttzhbjpmo74ilunghm4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33518761&oldid=1960718390"